BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.

@article{Neuendorff2015BCRABL1AM,
  title={BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.},
  author={Nina Rosa Neuendorff and Michaela Schwarz and Philipp Guido Hemmati and Seval Tuerkmen and Christiane Bommer and Thomas Burmeister and Bernd Doerken and Philipp le Coutre and Renate Arnold and J{\"o}rg Westermann},
  journal={Acta haematologica},
  year={2015},
  volume={133 2},
  pages={237-41}
}
The presence of a Philadelphia chromosome with a corresponding BCR-ABL1 rearrangement is the hallmark of chronic myeloid leukemia, but is considered a very rare event in de novo acute myeloid leukemia (AML). Here, we report the first case in which a dominant Philadelphia chromosome-positive subclone was detected upon relapse in a formerly Philadelphia chromosome-negative MLL-AF6(+) AML. Due to refractory disease under salvage chemotherapy, the patient was started on nilotinib treatment. As a… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS